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Abstract
Following a request from the European Commission, the EFSA Panel on Dietetic Products, Nutrition
and Allergies (NDA) was asked to update its scientiﬁc opinion on the safety of EstroG-100TM as a novel
food (NF) in the light of additional information submitted by the applicant. In its previous scientiﬁc
opinion of 2016, the Panel concluded that EstroG-100TM, which is a hot-water extract of a mixture of
three herbal roots, is safe for the use in food supplements at the maximum intake level of 175 mg/day
in post-menopausal women, which is lower than the maximum intake level proposed by the applicant
(514 mg/day). The Panel reached its conclusions based on the effects of EstroG-100TM on liver and
haematology as observed in several oral toxicity studies, the lack of information on liver and
haematological parameters in human studies and the absence of chronic toxicity data. In view of the
Panel’s conclusion on the safety of EstroG-100TM, the applicant has now provided additional information
on haematological and liver parameters for the human intervention study with EstroG-100TM and
historical control data related to the subchronic 90-day oral toxicity study with EstroG-100TM. After
assessing the additional information provided by the applicant, the Panel considers that the conclusion
of the scientiﬁc opinion on the safety of EstroG-100TM does not need to be revised, and thus, the
Panel reconﬁrms that the NF is safe for the use in food supplements at the maximum intake level of
175 mg/day in post-menopausal women.
© 2017 European Food Safety Authority. EFSA Journal published by John Wiley and Sons Ltd on behalf
of European Food Safety Authority.
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Summary
Following a request from the European Commission, the EFSA Panel on Dietetic Products, Nutrition
and Allergies (NDA) was asked to update its scientiﬁc opinion on the safety of EstroG-100TM as a novel
food (NF) in the light of additional information submitted by the applicant.
EstroG-100TM is a hot-water extract of a mixture of three herbal roots (Cynanchum wilfordii
Hemsley, Phlomis umbrosa Turcz. and Angelica gigas Nakai), which is concentrated and spray-dried. In
its previous scientiﬁc opinion of 2016, the Panel concluded that EstroG-100TM is safe for the use in food
supplements at the maximum intake level of 175 mg/day in post-menopausal women, which is lower
than the maximum intake level proposed by the applicant (514 mg/day). The Panel reached its
conclusions based on the effects of EstroG-100TM on liver and haematology (liver weight, reticulocytes,
erythrocytes, albumin and total protein levels) as observed in several oral toxicity studies, the lack of
information on liver and haematological parameters in human studies and the absence of chronic
toxicity data. In particular, the effects of EstroG-100TM on liver were observed in a 28-day and 90-day
oral toxicity study with EstroG-100TM, and in 90-day oral toxicity studies with two of the three single
constituents of EstroG-100TM.
In view of the Panel’s conclusion on the safety of EstroG-100TM, the applicant has now provided
additional information on haematological and liver parameters for the human intervention study with
EstroG-100TM and historical control data related to the subchronic 90-day oral toxicity study with
EstroG-100TM.
The Panel considers that historical control data may be used to assess the validity of the concurrent
control group but do not per se invalidate the ﬁndings in an animal experiment, in particular if these
ﬁndings were supported by those in other relevant studies.
The data provided on the human intervention study with EstroG-100TM, which lasted only 12 weeks,
reported no changes in liver and haematological parameters. However, the Panel considers that the
absence of changes in liver parameters in the short-period human intervention study is not enough to
dismiss the concerns on the effects of EstroG-100TM on liver which were consistently observed in four
repeated-dose oral toxicity studies (28-day and 90-day oral toxicity studies with EstroG-100TM and
90-day oral toxicity studies with two of the three single constituents of EstroG-100TM). Likewise, the
absence of changes in haematological parameters in the same human intervention study is not enough
to dismiss the concerns from the Panel on the effects of EstroG-100TM on haematological parameters
which were observed in the subchronic 90-day toxicity study with EstroG-100TM.
Thus, the Panel reconﬁrms that the no-observed-adverse effect level (NOAEL) derived from the
subchronic 90-day oral toxicity study with EstroG-100TM, which was supported by observations in other
studies, is 500 mg/kg body weight (bw) per day. By applying the uncertainty factor of 200 to the
NOAEL, the Panel has derived the maximum intake level of 2.5 mg/kg bw per day for the NF, which
corresponds to 175 mg/day for an adult of 70 kg bw.
After assessing the additional information provided, the Panel considers that the conclusion of the
scientiﬁc opinion on the safety of EstroG-100TM does not need to be revised and thus the
Panel reconﬁrms that the NF is safe for the use in food supplements at the maximum intake level of
175 mg/day in post-menopausal women.
Safety of EstroG-100TM
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1. Introduction
1.1. Background
On 21 September 2016, the EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA) adopted
the Scientiﬁc Opinion on the safety of an extract of three herbal roots (EstroG-100TM) as a novel food
ingredient in food supplements pursuant to Regulation (EC) No 258/971 (EFSA NDA Panel, 2016).
In that scientiﬁc opinion, the Panel concluded that, based on the existing data, the margin of safety
is not sufﬁcient at the maximum intake level proposed by the applicant.
The applicant has now provided additional information. In consequence, the applicant is asking to
review the additional information provided and, if necessary, to update the Scientiﬁc Opinion on the
safety of EstroG-100TM as a novel food (NF) ingredient in food supplements.
1.2. Terms of Reference as provided by the European Commission
In view of the above, the European Commission requests the European Food Safety Authority
(EFSA) to review the additional information provided by the applicant and, if necessary, to update the
conclusions of the Scientiﬁc Opinion on EstroG-100TM.
2. Data and methodologies
2.1. Data
The assessment of the safety of EstroG-100TM is based on the additional information provided by
the applicant on EstroG-100TM as annexed to this Mandate.
2.2. Methodologies
The assessment follows the methodology set out in Commission Recommendation 97/618/EC of
29 July 1997 concerning the scientiﬁc aspects and the presentation of information necessary to
support applications for the placing on the market of novel foods and novel food ingredients and the
preparation of initial assessment reports under Regulation (EC) No 258/97 of the European Parliament
and of the Council.
3. Assessment
On 21 September 2016, the NDA Panel adopted a Scientiﬁc Opinion on the safety of an extract of
three herbal roots (EstroG-100TM) as a NF in food supplements pursuant to Regulation (EC) No 258/97
(EFSA NDA Panel, 2016).
In that scientiﬁc opinion, the Panel concluded that EstroG-100TM is safe for the use in food
supplements at the maximum intake level of 175 mg/day in post-menopausal women, which is lower
than the maximum intake level proposed by the applicant (514 mg/day). The Panel reached its
conclusions based on the effects of EstroG-100TM on liver and haematology as observed in several oral
toxicity studies, the lack of information on liver and haematological parameters in human studies and
the absence of chronic toxicity data.
In view of the conclusion on the safety of EstroG-100TM, the applicant has now provided additional
information on haematological and liver parameters for the human intervention study by Chang et al.
(2012) and historical control data related to the subchronic 90-day oral toxicity study with EstroG-
100TM (Biotoxtech Co, 2015).
In the context of this new Mandate, the applicant has also provided an expert report on the safety
assessment of EstroG-100TM based on the available repeated-dose toxicity studies, which were already
assessed by the Panel in September 2016, and the registration status of EstroG-100TM since its
submission as a NF. The Panel considers that the review of the already assessed data and information
on the registration status of EstroG-100TM do not provide any additional information on the safety of
EstroG-100TM.
1 Regulation (EC) No 258/97 of the European Parliament and of the Council of 27 January 1997 concerning novel foods and
novel food ingredients. OJ L 43, 14.2.1997, p. 1–6.
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3.1. Haematological and liver parameters
As reported in the adopted scientiﬁc opinion on EstroG-100TM, the Panel has assessed the double-
blind, placebo-controlled study by Chang et al. (2012), in which 64 women with menopausal
symptoms were randomised to receive either EstroG-100TM (n = 31; 514 mg/day) or placebo (n = 33)
for 12 weeks (EFSA NDA Panel, 2016).
The applicant has now provided the results on haematological and liver parameters for this human
intervention study. In this respect, the Panel highlights that it is the duty of applicants to provide all
available scientiﬁc data that are pertinent to the safety of NF when submitting applications for NF.
Baseline and week-12 values of the following haematological and liver parameters have been
presented for each study group (EstroG-100TM and placebo): white blood cells, neutrophils, red blood
cells, haemoglobin, platelets, mean corpuscular volume (MCV), bilirubin, alanine aminotransferase
(ALT), aspartate aminotransferase (AST), creatinine, total protein, albumin, alkaline phosphatase and
blood urea nitrogen.
The applicant indicated that there was no ‘clinically signiﬁcant increase’ in liver parameters and no
‘clinically signiﬁcant changes’ in haematological parameters in the EstroG-100TM group.
3.2. Historical control data
As reported in the adopted scientiﬁc opinion on EstroG-100TM, the Panel has assessed the
subchronic 90-day oral toxicity with EstroG-100TM (doses of 0, 500, 1,000, or 2,000 mg/kg body weight
(bw) per day) (Biotoxtech Co, 2015) in Crl:CD(SD) rats. In this study, statistically signiﬁcant increases
in absolute and relative liver weights, albumin and total protein levels were reported at doses of
1,000 and 2,000 mg/kg bw per day (EFSA NDA Panel, 2016). This study also reported dose-related
increases in reticulocyte counts, which were statistically signiﬁcant only at the dose of 1,000 mg/kg bw
per day.
The applicant has now provided historical control data related to this subchronic 90-day oral toxicity
study (Lee et al., 2012). The historical control data were collected from 11 toxicity studies in Crl:CD
(SD) rats (n = 110 males; n = 110 females) over a period of 5 years at the Biotoxtech Co testing
facility.
The applicant commented that albumin and total protein levels as well as reticulocyte counts
reported in the subchronic 90-day toxicity study by Biotoxtech Co (2015) ‘match with the historical
control data’, and thus, the applicant considered these ﬁndings as not adverse. Historical control data
on absolute but not relative liver weights were provided.
4. Discussion
In the adopted scientiﬁc opinion on EstroG-100TM, the Panel noted that the subchronic 90-day oral
toxicity study by Biotoxtech Co (2015) reported statistically signiﬁcant increases in absolute and
relative liver weights, albumin and total protein levels in the EstroG-100TM high-dose and mid-dose
groups (2,000 mg/kg bw and 1,000 mg/kg bw per day) as compared to the control group. A
statistically signiﬁcant increase in relative liver weight was also reported in a 28-day oral toxicity study
in rats with EstroG-100TM at doses of 1,000 and 3,000 mg/kg bw per day as compared to the control
group (TTC Inc., 2015). Other subchronic 90-day oral toxicity studies with the constituents of EstroG-
100TM (Angelica gigas and Cynanchum wilfordii Hemsley) reported dose-related increases in absolute
and relative liver weight, total protein and albumin levels (Yun et al., 2015; Biotoxtech Co, 2016). The
subchronic 90-day oral toxicity study with EstroG-100TM also reported a dose-related increase in
reticulocytes in females, statistically signiﬁcant at the dose of 1,000 mg/kg bw per day as compared to
control group, and a decrease in erythrocytes, accompanied by an increase in MCV and mean
corpuscular haemoglobin in females at the dose of 2,000 mg/kg bw per day as compared to the
control group.
The Panel reiterates that the effects of EstroG-100TM on liver (weight, albumin and total protein
levels) were observed in the 28-day and 90-day oral toxicity studies with EstroG-100TM, which showed
a dose–response effect that increased with the duration of exposure as compared to the control group.
Similar dose-related effects on liver were also observed in 90-day oral toxicity studies with two of the
three single constituents of EstroG-100TM.
Historical control data were recently provided by the applicant for the 90-day oral toxicity study
with EstroG-100TM to show that albumin and total protein levels and reticulocyte counts in the test
group match with the historical control data. However, the Panel considers that historical control data
Safety of EstroG-100TM
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may be used to assess the validity of the concurrent control group but do not per se invalidate the
ﬁndings in an animal experiment, in particular if these ﬁndings were supported by those in other
relevant studies.
The data recently provided by the applicant on the human intervention study by Chang et al.
(2012), which lasted only 12 weeks, reported no changes in liver and haematological parameters.
However, the Panel considers that the absence of changes in liver parameters in the short-period
human intervention study is not enough to dismiss the concerns on the effects of EstroG-100TM on liver
which were consistently observed in the above-mentioned four repeated-dose oral toxicity studies (i.e.
statistically signiﬁcant increases in liver weight, albumin and total protein levels in the EstroG-100TM
groups as compared to the control group). Likewise, the absence of changes in haematological
parameters in the same human intervention study is not enough to dismiss the concerns from the
Panel on the effects of EstroG-100TM on haematological parameters which were observed in the
subchronic 90-day toxicity study with EstroG-100TM.
Thus, the Panel reconﬁrms that the NOAEL derived from the subchronic 90-day oral toxicity study
with EstroG-100TM (Biotoxtech Co, 2015), which was supported by observations in other studies, is
500 mg/kg bw per day. By applying the uncertainty factor of 200 to the NOAEL, the Panel has derived
the maximum intake level of 2.5 mg/kg bw per day for the NF, which corresponds to 175 mg/day for
an adult of 70 kg bw.
5. Conclusions
After assessing the additional information provided, the Panel considers that the conclusion of the
scientiﬁc opinion on the safety of EstroG-100TM does not need to be revised and thus the
Panel reconﬁrms that the NF is safe for the use in food supplements at the maximum intake level of
175 mg/day in post-menopausal women.
Steps taken by EFSA
1) On 11 January 2017, EFSA received the letter from the European Commission with the
request to review additional information in relation to the scientiﬁc opinion on the safety of
an extract of three herbal roots (EstroG-100TM) as a novel food ingredient. Ref. Ares(2017)
140603-11/1/2017.
2) On 19 January 2017, EFSA received from the European Commission the additional
information concerning the request above.
3) During its meeting on 4 April 2017, the NDA Panel, having evaluated the additional data,
adopted a statement on the safety of EstroG-100TM as a novel food pursuant to Regulation
(EC) No 258/97.
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Abbreviations
ALT alanine aminotransferase
AST aspartate aminotransferase
bw body weight
MCV mean corpuscular volume
NDA EFSA Panel on Dietetic Products, Nutrition and Allergies
NF novel food
NOAEL no-observed-adverse effect level
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